Aripiprazole Solution
Product Images NDC 72603-445

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72603-445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazolecartonlabel (Aripiprazolecartonlabel)

Packaging label for Aripiprazole Oral Solution 1 mg/mL, an oral liquid dosage form. The label indicates it contains 150 mL in one bottle and is manufactured for NorthStar Rx LLC, Memphis, TN. It includes storage instructions, pharmacist dispensing information, and a medication guide reference. The label shows the NDC 72603-445-01 and mentions the product is made in India by Hetero Labs Limited.*

FDA Label Image

Aripiprazolecontainerlabel (Aripiprazolecontainerlabel)

Aripiprazole Oral Solution 1 mg/mL bottle label displays product name, strength, and volume of 150 mL. It includes tamper-evident seal instructions, storage conditions, manufacturer details (Northstar Rx LLC and Hetero Labs Limited), and a note to dispense the Medication Guide. A barcode and lot information are also visible.*

FDA Label Image

Aripiprazolefigure1 (Aripiprazolefigure1)

A scatter plot showing the effect of various other drugs on aripiprazole pharmacokinetics. The x-axis represents change relative to reference (without interacting drug) from 0.5 to 3.0, and the y-axis lists CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs valproate, lithium, and lorazepam. Each drug's impact on aripiprazole AUC and Cmax with 90% confidence intervals is shown.*

FDA Label Image

Aripiprazolefigure2 (Aripiprazolefigure2)

A horizontal scatter plot titled 'Effect of Other Drugs on Aripiprazole' displaying fold change in dehydro-aripiprazole pharmacokinetics with 90% confidence intervals. The y-axis lists interacting drug categories such as CYP3A4 inhibitors, CYP2D6 inhibitors, inducers, gastric acid blockers, and others. The x-axis shows change relative to reference without interacting drugs, ranging from 0.5 to 3.0 fold.*

FDA Label Image

Aripiprazolefigure3 (Aripiprazolefigure3)

A forest plot chart showing the effect of Aripiprazole on other drugs by comparing pharmacokinetic parameters (AUC and Cmax) with fold change and 90% confidence intervals. The chart lists various drugs and enzymes including CYP2D6, CYP2C9, CYP2C19, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, illustrating their relative changes when interacting with Aripiprazole oral solution.*

FDA Label Image

Aripiprazolefigure4 (Aripiprazolefigure4)

A graph depicting Aripiprazole fold change and 90% confidence intervals for special populations including CYP2D6 metabolizer status, gender, age groups, hepatic impairment (mild, moderate, severe), and severe renal impairment. The x-axis shows change relative to reference from 0.5 to 3.0, with plotted points and error bars for AUC and Cmax measures.*

FDA Label Image

Aripiprazolefigure5 (Aripiprazolefigure5)

A pharmacokinetic (PK) chart titled 'Dehydro-aripiprazole Fold Change and 90% CI' illustrating changes in area under the curve (AUC) ratios relative to a reference for various factors including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment.*

FDA Label Image

Aripiprazolefigure6 (Aripiprazolefigure6)

A line graph showing the proportion of subjects with relapse over days from randomization for Aripiprazole compared to placebo. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse. The graph includes a table indicating the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Aripiprazolefigure7 (Aripiprazolefigure7)

A Kaplan-Meier curve chart comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The graph includes the number of subjects at risk for each group at various time points along the study duration of up to 182 days.*

FDA Label Image

Aripiprazolefigure8 (Aripiprazolefigure8)

A Kaplan-Meier survival curve graph comparing Aripiprazole and placebo groups. The y-axis represents the proportion with relapse, and the x-axis shows days from randomization up to 182 days. The number of subjects at risk is listed below the x-axis for both groups at multiple time points.*

FDA Label Image

Aripiprazolefigure9 (Aripiprazolefigure9)

Line graph showing change in YGTSS total tic score from baseline over weeks of treatment comparing Aripiprazole low dose, Aripiprazole high dose, and placebo groups. The x-axis represents weeks of treatment, and the y-axis shows least-squares mean change in tic score, with tic score decreasing (improving) over time for Aripiprazole groups compared to placebo.*

FDA Label Image

Aripiprazolestructure (Aripiprazolestructure)

Chemical structure of Aripiprazole, illustrating the molecular composition and bonding pattern characteristic of this active pharmaceutical ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.